



**Supplemental Figure S1. Generation of CRISPR-corrected hiPSC line and differentiation methods to generate iGABA and iNs.**

**(A)** Summary of clinical features and human iPSCs lines from SSADH deficient patients, sex-matched unaffected parental controls and CRISPR corrected lines. **(B)** SSADH Asp409Gly reversion using CRISPR and ssODN to generate *ALDH5A1*<sup>corr/corr</sup>. **(C)** Design of construct and schematic presentation of the iGABA neurons differentiation protocol and assays. **(D)** Design of construct and schematic presentation of the iNs differentiation protocol and assays.




**Figure S2. Generation and characterization of the hiPSCs used in this study**

(A,B,E) Successful reprogramming by characterizing the expression of pluripotency markers. Top panel: NANOG (Nanog homeobox x in green) and TRA-1-60 (podocalyxin in magenta). Bottom panel: OCT4 (octamer binding transcription factor 4 in green), SOX2 (SRY-Box Transcription Factor 2 in magenta), in undifferentiated pluripotent hiPSC colonies. (C,D,F) G-banded karyotype post-transduction with pLV-TetO-hNGN2-P2A-mCherry-T2A-Puro (hNGN2-mCherry) or pLV-TetO-hDLX2-P2A-hASCL1-T2A-Puro (hDLX2-hASCL1) showing a normal karyotype for all lines.



**Figure S3. Characterization of iGABA neurons from Family 002 and 003**


(A) Representative images of iGABA neurons from family 002 parental control (*ALDH5A1*<sup>+/+</sup>) and patient (*ALDH5A1*<sup>-/-</sup>) at DIV 55 in co-culture with hiPSC-derived astrocytes labeled with DAPI (cyan), MAP2 (green), GABA (magenta). Scale bar 100µm and quantification of GABA-positive neurons over MAP2 positive neurons showing no significant difference between all three genotypes used in this study (n=3). (B) Western blot of SSADH expression from family 002 iGABA neurons from all genotypes and SSADH-deficient neurons treated for 72hours at DIV 35. Quantification of SSADH levels from three separate transfections displayed as percentage of parental control (*ALDH5A1*<sup>+/+</sup>) (mean ± s.e.m. values; n=3; \*\*\*p < 0.001, \*\*p < 0.01; two-way ANOVA with Tukey's multiple comparisons test; F (2, 4) = 132.1). (C) ELISA quantification of GHB in family 002 iGABA neurons at DIV 35 and after 72hours treatment with mRNA (-/- treated) reveals significant increase in *ALDH5A1*<sup>-/-</sup> neurons and decrease following mRNA treatment (mean ± s.e.m. values; n=3 separate transfections; \*\*\*\*p < 0.0001; \*\*\*p < 0.001; ns=non-significant; two-way ANOVA with Tukey's multiple comparisons test; F (2, 4) = 409.6). (D) Representative images of iGABA neurons from family 003 parental control (*ALDH5A1*<sup>+/+</sup>) and patient (*ALDH5A1*<sup>-/-</sup>) at DIV 55 in co-culture with hiPSC-derived astrocytes labeled with DAPI (cyan), MAP2 (green), GABA (magenta). Scale bar 100µm and quantification of GABA-positive neurons over MAP2 positive neurons showing no significant difference between all three genotypes used in this study (n=3). (E) Western blot of SSADH expression from family 003 iGABA neurons from all genotypes at DIV 35. Quantification of SSADH levels from three separate differentiations displayed as percentage of parental control (*ALDH5A1*<sup>+/+</sup>) (mean ± s.e.m. values; n=3; \*\*\*\*p < 0.0001, unpaired t-test, two-tailed; t=15.59, df=4). (F) ELISA quantification of GHB in family 003 iGABA neurons at DIV 35 showing significant increase in *ALDH5A1*<sup>-/-</sup> (n=3 independent differentiations; \*\*\*p < 0.001, unpaired t test; two-tailed; t=42.06, df=2).



**Figure S4. Characterization of iNs from Family 002 and 003**

(A) Representative images of hiPSC-derived iNs from family 002 parental control (*ALDH5A1*<sup>+/-</sup>) and patient (*ALDH5A1*<sup>-/-</sup>) at DIV 55 in co-culture with hiPSC-derived astrocytes labeled with DAPI (cyan), MAP2 (green) and TBR1 (magenta). Scale bar 100µm. Quantification of TBR1-positive neurons over MAP2-positive neurons showed no significant difference between all three genotypes used in this study (mean ± s.e.m. values; n=3; ns=non-significant). (B) Western blot of SSADH expression from family 002 iNs DIV 30. Quantification of SSADH levels from three separate differentiations normalized to β-actin and displayed as a percentage of parental control (*ALDH5A1*<sup>+/-</sup>) (mean ± s.e.m. values; n=3; \*\*\*p < 0.001; unpaired t test; two-tailed; t=13.04, df=4). (C) Normalized family 002 iNs neurite length per cell-body cluster area [phase] (mm/mm<sup>2</sup>) demonstrates significantly longer neurites in *ALDH5A1*<sup>-/-</sup> compared to controls (mean ± s.e.m. values; n=3; \*\*\*\*p < 0.0001; paired t test; two-tailed; t=6.694, df=12). (D-H) Multi electrode array analysis at DIV 50 (mean ± s.e.m.; n=3 independent differentiations; 24 independent wells per differentiation; one-way ANOVA with Tukey's multiple comparisons test; \*\*\*\*p < 0.0001; \*\*p < 0.01). (I) Representative images of hiPSC-derived iNs from family 003 parental control (*ALDH5A1*<sup>+/-</sup>) and patient (*ALDH5A1*<sup>-/-</sup>) at DIV 55 in co-culture with hiPSC-derived astrocytes labeled with DAPI (cyan), MAP2 (green) and TBR1 (magenta). Scale bar 100µm. Quantification of TBR1-positive neurons over MAP2-positive neurons showed no significant difference between all three genotypes used in this study (mean ± s.e.m. values; n=3; ns=non-

significant). **(J)** Western blot of SSADH expression from family 003 iNs at DIV 30. Quantification of SSADH levels from three separate differentiations normalized to  $\beta$ -actin and displayed as a percentage of parental control (*ALDH5A1*<sup>+/-</sup>) (mean  $\pm$  s.e.m. values; n=3; \*\*p < 0.01) **(K)** Normalized family 003 iNs neurite length per cell-body cluster area [phase] (mm/mm<sup>2</sup>) demonstrates significantly longer neurites in *ALDH5A1*<sup>-/-</sup> compared to controls (mean  $\pm$  s.e.m. values; n=3; \*\*\*\*p < 0.0001; paired t test; two-tailed; t=5.795, df=12).



**Figure S5. RNA Sequencing in iGABA and iNs**

**(A)** The network plot of the top 1,000 connections within the ME77 module, where each node represents a gene, and the edges represent connections based on Topological Overlap. Genes associated with synaptic function are labeled. **(B)** Gene Set Enrichment Analysis of ASD risk genes obtained from the SFARI database (Category 1) compared to connectivity within ME77 module;  $n=3$  independent differentiations. **(C)** The cumulative distribution function of genes in the ME77 module displays the fold changes comparing proband to control in the iGABA (red) and iNs (blue) neurons. **(D)** The cumulative distribution function of fold changes comparing control iGABA to control iNs for genes in the ME77 module (red) and all other genes (gray). **(E)** The cumulative distribution function of genes in the ME54 module displays the fold changes comparing proband to control in the iGABA (red) and iNs (blue) neurons. **(F)** The cumulative

distribution function of fold changes comparing control iGABA to control iNs for genes in the ME54 module (blue) and all other genes (gray).